Drosophila melanogaster as a model for unraveling unique molecular features of epilepsy elicited by human GABA transporter 1 variants

dc.contributor.author Ameya S. Kasture
dc.contributor.author Florian P. Fischer
dc.contributor.author Ali El-Kasaby
dc.contributor.author Thomas Hummel
dc.contributor.author Ameya S. Kasture
dc.contributor.author Florian P. Fischer
dc.contributor.author Lisa Kunert
dc.contributor.author Melanie L. Burger
dc.contributor.author Alexander C. Burgstaller
dc.contributor.author Sonja Sucic
dc.date.accessioned 2025-06-16T13:58:59Z
dc.date.available 2025-06-16T13:58:59Z
dc.date.issued 2023-01-19
dc.description.abstract <jats:p>Mutations in the human γ-aminobutyric acid (GABA) transporter 1 (hGAT-1) can instigate myoclonic-atonic and other generalized epilepsies in the afflicted individuals. We systematically examined fifteen hGAT-1 disease variants, all of which dramatically reduced or completely abolished GABA uptake activity. Many of these loss-of-function variants were absent from their regular site of action at the cell surface, due to protein misfolding and/or impaired trafficking machinery (as verified by confocal microscopy and de-glycosylation experiments). A modest fraction of the mutants displayed correct targeting to the plasma membrane, but nonetheless rendered the mutated proteins devoid of GABA transport, possibly due to structural alterations in the GABA binding site/translocation pathway. We here focused on a folding-deficient A288V variant. In flies, A288V reiterated its impeded expression pattern, closely mimicking the ER-retention demonstrated in transfected HEK293 cells. Functionally, A288V presented a temperature-sensitive seizure phenotype in fruit flies. We employed diverse small molecules to restore the expression and activity of folding-deficient hGAT-1 epilepsy variants, <jats:italic>in vitro</jats:italic> (in HEK293 cells) and <jats:italic>in vivo</jats:italic> (in flies). We identified three compounds (chemical and pharmacological chaperones) conferring moderate rescue capacity for several variants. Our data grant crucial new insights into: (i) the molecular basis of epilepsy in patients harboring hGAT-1 mutations, and (ii) a proof-of-principle that protein folding deficits in disease-associated hGAT-1 variants can be corrected using the pharmacochaperoning approach. Such innovative pharmaco-therapeutic prospects inspire the rational design of novel drugs for alleviating the clinical symptoms triggered by the numerous emerging pathogenic mutations in hGAT-1.</jats:p>
dc.description.volume 16
dc.identifier.doi 10.3389/fnins.2022.1074427
dc.identifier.doi 10.18154/rwth-conv-250695
dc.identifier.handle 11353/10.2045838
dc.identifier.issn 1662-453X
dc.identifier.openaire doi_dedup___
dc.identifier.pmc PMC9893286
dc.identifier.pmid 36741049
dc.identifier.uri https://ror.circle-u.eu/handle/123456789/644296
dc.openaire.affiliation University of Vienna
dc.openaire.collaboration 1
dc.publisher Frontiers Media SA
dc.rights OPEN
dc.rights.license CC BY
dc.source Frontiers in Neuroscience
dc.subject folding
dc.subject Epilepsy
dc.subject -aminobutyric acid (GABA)
dc.subject Neurosciences. Biological psychiatry. Neuropsychiatry
dc.subject 106025 Neurobiology
dc.subject Drosophila melanogaster
dc.subject SDG 3 - Good Health and Well-being
dc.subject trafficking
dc.subject GABA transporter 1
dc.subject uptake
dc.subject SDG 3 – Gesundheit und Wohlergehen
dc.subject epilepsy
dc.subject transporter disease variants
dc.subject γ -aminobutyric acid (GABA)
dc.subject 4-phenylbutyrate, uptake
dc.subject protein folding and trafficking
dc.subject 106025 Neurobiologie
dc.subject 4-phenyl butyric acid
dc.subject RC321-571
dc.subject Neuroscience
dc.subject.fos 0303 health sciences
dc.subject.fos 03 medical and health sciences
dc.title Drosophila melanogaster as a model for unraveling unique molecular features of epilepsy elicited by human GABA transporter 1 variants
dc.type publication

Files

Collections